Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Baker Ruskinn, formerly Ruskinn Life Sciences, is a global leader in the design and manufacture of anaerobic and precision low-oxygen (hypoxia) workstations for laboratory use. Their specialized chambers allow researchers to cultivate and manipulate cells in environments that precisely mimic in vivo physiological conditions, which is critical for research in cancer, stem cells, and microbiology. The company's flagship product lines, including the InvivO2 and Sci-tive series, provide highly controlled atmospheres with precise regulation of oxygen, carbon dioxide, temperature, and humidity. Founded in 1993 and based in Bridgend, South Wales, the company was acquired by The Baker Company in 2011. Today, Baker Ruskinn continues to innovate in the field of 'physoxia' to help scientists better understand cellular behavior in health and disease.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ruskinn Life Sciences.